These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21433320)

  • 1. [Sexual dysfunction in women with overactive bladder and their correction with m-cholinolytic spasmex].
    Danilova TI; Danilov VV; Luchinskiĭ SA; Danilov VV; Vasil'chenko AV
    Urologiia; 2010; (6):30-4. PubMed ID: 21433320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [M-cholinolytic spasmex and its role in preoperative preparation of patients with urine incontinence].
    Danilov VV; Danilova TI
    Urologiia; 2007; (1):33-6. PubMed ID: 17471995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Spasmex treatment of patients with hyperactive urinary bladder].
    Pushkar' DIu; Shchaveleva OB
    Urologiia; 2003; (4):46-9. PubMed ID: 12942728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and urodynamic rationale of the overactive bladder neurophysiological model].
    Danilov VV; Danilova TI; Danilov VV
    Urologiia; 2010; (4):15-20. PubMed ID: 20967977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
    Neĭmark AI; Riapolova MV; Mel'nik MA
    Urologiia; 2010; (2):36-8. PubMed ID: 20967993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Substantiation of the duration of m-cholinolytics administration in conservative treatment of hyperactive urinary bladder].
    Danilov VV; Vol'nykh IIu; Danilova TI; Vodop'ianova OA; Kudriakova NA
    Urologiia; 2006; (5):71-4. PubMed ID: 17444156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
    Mazo EB; Babanina GA
    Urologiia; 2007; (3):15-9. PubMed ID: 17722614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.
    Sand PK; Johnson Ii TM; Rovner ES; Ellsworth PI; Oefelein MG; Staskin DR
    BJU Int; 2011 Feb; 107(4):612-20. PubMed ID: 20707790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of overactive bladder in women with vitaprost forte].
    Gomberg VG; Nad' IuT
    Urologiia; 2010; (4):20-5. PubMed ID: 20967978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of symptoms severity in patients with overactive bladder].
    Al'-Shukri SKh; Kuz'min IV
    Urologiia; 2008; (6):37-40. PubMed ID: 19248597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Giacomo Novara, Antonio Galfano, Silvia Secco, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64.
    Staskin DR; Oefelein MG
    Eur Urol; 2009 May; 55(5):e84-5; author reply e86-7. PubMed ID: 18963417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.